Diagnosing Li-Fraumeni syndrome soon after a patient’s first cancer can reduce their overall cancer burden with an improved, personalized plan. Faster identification enables earlier screening, proactive prevention, and better-informed treatment choices that minimize the risk of therapy-induced secondary cancers in women. Read more on the research published in Clinical Breast Cancer (June 2026) by our friends at UT MD Anderson Cancer Center, host of the 8th International LFS Association Symposium in October 2026.
